Hormonal therapy (AR inhibitor)
Xtandi (enzalutamide) cost
Manufacturer: Astellas / Pfizer · Route: oral (Part D) · Last updated
Medicare spending — 2023
$90,778
Average total Medicare spending per beneficiary per year
$13,574
Average spending per prescription filled
$13,574
Typical monthly pharmacy fill
Source: CMS Medicare Part D Spending by Drug, data year 2023.
What patients actually pay
The $90,778 figure above is total Medicare spending — the government's payment — not what a patient pays out of pocket. Actual out-of-pocket varies widely:
- Original Medicare + Medigap supplemental policy: typically covers most of the 20% Part B coinsurance, leaving minimal out-of-pocket.
- Medicare Advantage: caps annual out-of-pocket spending ($8,850 in 2024 for in-network care, lower for some plans).
- Commercial insurance: copay or coinsurance varies; specialty drugs often require prior authorization. See "financial assistance" below.
- Uninsured: manufacturer patient assistance programs can provide Xtandi at no cost for income-eligible patients. See below.
Cancers this drug treats
FDA-approved indications for Xtandi on our site. For each, see the complete treatment landscape plus active clinical trials.
Financial assistance for Xtandi
The manufacturer of Xtandi offers a patient assistance program. Disease-specific foundations also fund copay assistance for the cancers this drug treats.
Pfizer Oncology Together
Manufacturer programbenefit investigation · copay assistance · patient assistance program (uninsured)
https://www.pfizeroncologytogether.com/ · 877-744-5675
Disease foundations with funds covering Xtandi's cancers
HealthWell Foundation
copay, premium, and deductible assistance for insured patients; fund availability varies by disease
https://www.healthwellfoundation.org/disease-funds/
Funds open and close based on availability; check disease-funds page for current status
Patient Access Network (PAN) Foundation
copay assistance for 20+ cancer types via disease-specific funds
https://www.panfoundation.org/find-disease-fund/ · 866-316-7263
Merging with Patient Advocate Foundation; unified 'TotalAssist' program launches 2026-07-01
Patient Advocate Foundation Co-Pay Relief
direct copay / coinsurance assistance via disease-specific funds
https://copays.org/ · 866-512-3861
Merging with PAN Foundation; launching 'TotalAssist' 2026-07-01
CancerCare Co-Payment Assistance Foundation
copay assistance for chemotherapy and targeted treatment medications
https://www.cancercare.org/copayfoundation · 866-552-6729
CancerCare Financial Assistance
limited financial assistance for transportation, home care, child care, and treatment-related costs
https://www.cancercare.org/financial · 800-813-4673
Good Days
copay and premium assistance for chronic disease treatments
URL pending re-validation; disease fund availability varies
Also try these directory aggregators: NeedyMeds, RxAssist, Cancer Financial Assistance Coalition (CFAC).
Clinical trials using Xtandi
Trials testing enzalutamide in new combinations, new cancer types, or earlier lines of therapy. Trials often cover the cost of the drug.
Or search ClinicalTrials.gov directly for enzalutamide.